Intervention

AFP464

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions11

Lead sponsors shown2

Clinical trials

2 shown

Study of AFP464 +/- Faslodex in ER + Breast CancerNCT01233947 · 2011-05-01

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryNCT00348699 · 2006-07-01

Common conditions

Breast Neoplasm1 Male Breast Cancer1 Recurrent Breast Cancer1 Recurrent Ovarian Epithelial Cancer1 Recurrent Primary Peritoneal Cavity Cancer1 Recurrent Renal Cell Cancer1 Stage IV Breast Cancer1 Stage IV Ovarian Epithelial Cancer1 Stage IV Primary Peritoneal Cavity Cancer1 Stage IV Renal Cell Cancer1 Unspecified Adult Solid Tumor, Protocol Specific1

Leading sponsors

National Cancer Institute (NCI)1 Tigris Pharmaceuticals1

Trial status mix

COMPLETED1

TERMINATED1

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.